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Abstract: Amplicons are helper-dependent herpes simplex virus type 1 (HSV-1)-based vectors that can deliver very large 
foreign DNA sequences and, as such, are good candidates both for gene delivery and vaccine development. However, 
many studies have shown that innate constitutive or induced cellular responses, elicited or activated by the entry of HSV-1 
particles, can play a significant role in the control of transgenic expression and in the induction of inflammatory 
responses. Moreover, transgene expression from helper-free amplicon stocks is often weak and transient, depending on 
the particular type of infected cells, suggesting that cellular responses could be also responsible for the silencing of 
amplicon-mediated transgene expression. This review summarizes the current experimental evidence underlying these 
latter concepts, focusing on the impact on transgene expression of very-early interactions between amplicon particles and 
the infected cells, and speculates on possible ways to counteract the cellular protective mechanisms, thus allowing stable 
transgene expression without enhancement of vector toxicity. 
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INTRODUCTION 
  Pathogenic viruses and their hosts coevolved during 
millions of years and have developed adaptive features that 
allow the survival of both. The vast number and outstanding 
complexity of self-protective mechanisms is a clear 
illustration of the strength of the selective pressures that 
viruses and their hosts have imposed to each other. The 
number of genes involved in the setting up and management 
of the two arms of the adaptive immune system, as well as in 
the signalling, coordination, and execution of non-specific 
inducible innate mechanisms, such as the interferon (IFN), 
the inflammatory, and the pro-apoptotic responses, is 
overwhelming. The sophistication of other mechanisms, such 
as autophagy, the complement cascade, or the more recently 
recognized set of functions that can act as constitutive 
intracellular barriers through the silencing of viral gene 
expression, all concur to demonstrate that a significant 
fraction of the host genome is devoted to these self-
protective activities. 
  The same consideration is valid for viruses, at least for 
some of them. Viruses have evolved complex phenotypes 
that can be thought as operating to mask their presence 
within the organism or within the cells, such as latency or 
any other form of controlled and reversible gene silencing, 
integration of their genomes within cellular chromosomes, 
expression of non-immunogenic proteins, and disruption or 
diversion of the host defences. The end-result of this struggle 
is that, while the hosts generally prevail at the level of the 
whole organism, thus resulting in host survival, lytic viruses  
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most often gain the battle at the cellular level, thus 
warranting virus survival and dissemination. However, 
viruses have small genomes and express a limited amount of 
proteins, suggesting that they can act only on a few key 
elements of the host responses and should gather together 
several functions into a single protein. 
  In the case of large nuclear DNA viruses, such as herpes 
simplex virus type 1 (HSV-1) the number of genes that are 
devoted to the virus self-protective activities is quite large, 
representing some 15% of the virus encoded proteins. As 
illustrated in Table 1, HSV-1 has developed functions able to 
efficiently counteract most of the above mentioned host 
defences. Some HSV-1 proteins, such as US3, ICP0, and 
ICP34.5, can supply more than one activity and play more 
than one role in supporting virus multiplication [1-6]. Other 
proteins, such as vhs (UL41) and ICP27 (UL54), probably 
act through non-specific mechanisms, as both of them are 
independently able to down-regulate expression of most 
cellular proteins [7, 8]. Other proteins, such as ICP47 
(UL12), gD, gC, gJ, gE, or US11, seem to play specific roles 
in counteracting more defined cellular responses [9-15]. 
Another virus protein, known as ICP4, has also been 
involved in escaping cellular responses, but it is not yet clear 
whether there is a direct involvement of ICP4 or if its 
contribution stems from the fact that ICP4 is a regulatory 
protein required for the expression of other classes of virus 
proteins [16]. Table 1 presents a summary of the cellular 
protective mechanisms acting against HSV-1 infection as 
well as the HSV-1 functions that are involved in 
counteracting the host responses. 
  It should be stressed, however, that the ability to 
counteract host responses is a feature only of wild type virus. 
Viral vectors, in contrast, are non-natural entities that have 
been developed with the aim to deliver genes for therapeutic 
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vectors should be safe, both for the whole organism and for 
the infected cells. In order to decrease virus toxicity and 
preserve the transduced cells, one or more viral genes are 
often deleted or inactivated, therefore resulting in the direct 
or indirect silencing of genes that are involved in virus 
survival in the cellular environment [17]. As a consequence, 
the infected cells will also succeed in the struggle at the 
cellular level, and the vector genome, together with the 
therapeutic transgenes, will be silenced or eliminated [18], 
which constitutes a major hurdle for the use of defective 
vectors in gene therapy approaches. 
  High-capacity vectors, such as HSV-1-derived amplicon 
vectors [19, 20], are extreme cases since they carry no virus 
genes and therefore express no virus functions in the 
transduced cells. This implies that all virus self-protective 
functions are absent, with the only exception of the functions 
carried by the structural proteins that are introduced in the 
cells during entry of vector particles, which have 
nevertheless a limited half-life and will soon disappear. This 
is probably at the basis of the low or transient expression 
often observed with helper-free amplicon vectors, both in 
cultured cells and in experimental animals [21, 22]. Actually, 
many observations suggest that expression from helper-free 
amplicons is transient in many experimental settings and that 
the length and intensity of transgene expression is cell-type 
specific. Indeed, after infection of dividing cells, the loss of 
the amplicon genomes is fast since there is no vector 
amplification in the infected cells and the genome will 
therefore be diluted concomitantly with cell proliferation. 
However, also in cells that do not divide the amplicon 
genome is often expressed during a relatively short time, and 
this is not related to cell death. Therefore, the amplicon 
genome probably becomes silenced. There are no complete 
answers yet to explain why transgenic expression from an 
amplicon genome becomes extinct in the absence of helper 
proteins. Nevertheless, at least two non-mutually exclusive 
hypotheses may be advanced to explain failure to obtain 
stable and strong transgene expression from the amplicon 
genome. These are based either (i) on the induction of innate 
immune responses able to repress transgene expression, or 
(ii) on the action of constitutive cellular functions able to 
induce transcriptional silencing of the disabled vector 
genome. This review will focus on the evidences supporting 
these cellular responses, and will consider some possible 
ways to counteract these mechanisms without enhancing 
vector toxicity. 
AMPLICON VECTORS 
  Amplicons are defective, helper-dependent vectors that 
carry no viral genes and take advantage of the large carrier 
capacity of the virus particle to deliver long transgenic 
sequences [19, 20]. There is currently no other vector that 
equals the ability of amplicons to safely deliver almost 150 
Kbp of foreign DNA to the nucleus of mammalian cells. 
  The genome of amplicon vectors derives from a plasmid, 
named the amplicon plasmid, which carries one packaging 
signal and one origin of DNA replication from HSV-1. As it 
carries no virus genes, this plasmid requires the presence of a 
helper virus genome to express the proteins necessary for its 
amplification and packaging into HSV-1 particles. Over the 
last decade, technological improvements have enabled the 
production of relatively large amounts of amplicon stocks 
Table 1.  Host Defence Mechanisms and HSV-1 Genes Involved in Disarming Cellular Responses 
 
Host Defence Virus gene Involved in Counteraction Mechanisms
Complement cascade gC (UL44) 
 
gE (US7)
Binds C3b [14, 52] 
Inhibits C5 and factor P (properdin) binding [15] 
Fc receptor activity [53]
Intrinsic 
innate responses
ICP0 (RL2) E3-Ubiquitin-ligase. Induces proteolysis of transcriptional silencers [41-45]
Inducible 
innate responses 
 
a) Interferons 
b) Inflammation
ICP0 (RL2) 
ICP27 (UL54) 
ICP34.5 (RL1) 
US11 
Vhs (UL41) 
 
US3
Inhibition of IRF3 signalling [3, 4, 54-56] 
Blocks splicing. Inhibits activation of IRF3 and STAT1 [8, 57] 
Dephosphorylates eIF2 . Prevents IRF3 activation [3, 5, 12, 58, 59] 
Interacts with PKR, prevents production of 2’-5’ OAS [12, 60, 61] 
Inhibits ISG transcription and STAT1 phosphorylation. Induces degradation of 
cellular mRNA [7, 54, 62] 
Post-translational modification of IFN receptors and inhibition of ISG induction 
[2, 63]
Inducible 
innate responses 
 
a) Apoptosis 

US3 
 
ICP4 (RS1) 
ICP27 (UL54) 
gD (US6) 
gJ (US5) 
LAT
Activates PKA and phosphorylates the same targets as PKA (Bad, Bid, procaspase 
3) [1, 64-67] 
Regulatory protein [16, 68, 69]. 
Activates NFB and stabilizes Bcl2 [70, 71] 
Activates NFB. Protection against FAS-mediated apoptosis [11, 72] 
Prevents apoptosis induced by UV, anti-FAS or CTL killing [10, 11] 
Inhibits apoptosis during HSV-1 latency [73, 74]
Autophagy ICP34.5 (RL1) Binding and inhibition of Beclin 1 (Atg-6) [6]
Adaptive 
immune response
gE (US7) 
ICP47 (UL12)
Fc receptor activity [13] 
Binding and inhibition of human TAP [9]98    The Open Virology Journal, 2010, Volume 4  Tsitoura and Epstein 
that are, not or only, minimally contaminated with helper 
virus particles [23-26], and to use these vectors to deliver 
long genomic sequences to target cells [27-30]. These major 
breakthroughs have made it possible to study important 
aspects of the biological features of amplicons in the absence 
of helper HSV-1. However, our understanding of amplicon 
biology remains fragmentary in many aspects. 
  In addition to their applications as gene delivery vectors, 
amplicons are powerful tools to investigate HSV-1 functions 
[31-33]. Since amplicons carry no virus genes, they can be 
used to study very early interactions between HSV-1 
particles and host cells, including the innate cellular 
responses elicited by virus entry, thus avoiding the 
requirement to use virus mutants, chemicals, or UV-
inactivation of virus particles [34]. UV-treatment of the virus 
may disrupt the protein structure of the particles affecting 
entry and may crosslink viral proteins and nucleic acids 
affecting nuclear release of the genome. Amplicons, in 
contrast, are able to normally penetrate cells, target their 
genome to the nucleus and are transcriptionally active. 
Furthermore, the amplicon genome can be engineered to 
express selected viral or cellular proteins potentially 
affecting early virus host interactions, thereby allowing 
analyzing how these functions modulate the cellular 
responses [21]. Since the presence of proteins expressed 
from helper particles in helper-contaminated (HC)-amplicon 
stocks can affect induction of cellular responses, in the 
following paragraphs we will focus mainly on studies 
conducted with helper-free (HF)-amplicon stocks, or with 
amplicon stocks only barely contaminated (less than 1%) 
with defective helper particles. 
INDUCTION OF INNATE RESPONSES IN 
AMPLICON-INFECTED CELLS 
  Only a few studies have addressed the cellular responses 
elicited by HF-amplicons. In an early study, designed to 
develop an immunotherapeutic approach for chronic 
lymphocytic leukemia (CLL), Tolba et al. compared the 
ability of HF-amplicons and HC-amplicons, expressing 
CD80 (B7.1) or CD154 (CD40L), to transduce human CLL 
B cells and to induce immune responses [35]. Results from 
this study indicated that although both HF and HC amplicon 
stocks were equivalent in their ability to transduce CLL 
cells, a robust T-cell proliferative response was observed 
only with the HF-amplicons. The authors concluded that HF-
amplicons were better suited for immunotherapy than HC-
vectors and that a strong immunosuppressive activity was 
associated with the helper particles present in the HC-
amplicon stocks [35]. In a more recent study, and using a 
similar approach, the same group identified the viral ICP0 
protein, which is expressed only in the HC-amplicon stocks, 
as an inhibitor of the TLR-mediated inflammation. Further, 
they showed that ICP0 is able to block NF-B and JNK 
activation downstream of TLR signal activation and that this 
process depends on ICP0-mediated translocation of the 
deubiquinating enzyme USP7 from the nucleus to the 
cytoplasm, where this enzyme binds to and deubiquitinates 
TRAF6 and IKK, thus terminating the TLR response [36]. 
  HF-amplicons can induce a significant inflammatory 
response also in the mouse brain, but this response is 
considerably lower than that observed using HC-amplicon 
stocks [37]. In one study, C57BL/6 mice were 
stereotactically inoculated with -galactosidase expressing 
amplicons, either contaminated or not with HSV-1 helper 
particles. After killing the mice, at 1 or 5 days post-
transduction, samples were analysed for various cytokine, 
chemokine, and adhesion molecule gene expression using 
immune-cytochemistry and RT-PCR. Results indicated that 
both vector stocks induced inflammation, with blood-brain 
barrier opening, on day 1. By day 5, mRNA levels of the 
inflammatory cytokines IL-1, TNF, or IFN, chemokines, 
such as MCP1 and IP-10, and adhesion molecule ICAM1, 
had returned to baseline in saline injected mice and to near 
baseline in animals injected with HF-amplicon stocks. In 
contrast, mice inoculated with HC-amplicon stocks showed 
elevated inflammatory molecule expression and immune cell 
infiltration even at day 5 post-injection. This study therefore 
confirmed that, although contaminating viral proteins could 
play a major role in the induction of inflammation in the 
brain, HF-amplicon vectors did induce cellular inflammatory 
responses in the infected host. 
  Other studies have focused on the IFN responses elicited 
by amplicons [38, 39]. A first investigation showed that, 
after systemic delivery of HF-amplicon vectors into mice, 
early activation of the signal transducer and activator of 
transcription 1 (STAT1) transcription factor, a key IFN-
activated signalling molecule, suppresses transcription of the 
vector-encoded transgene (luciferase) in the liver [38]. A 
similar experiment conducted in STAT1-knockout mice 
showed 10-fold higher luciferase expression than in wild-
type mice, and this expression remained detectable during at 
least 80 days, while in wild-type mice luciferase expression 
became undetectable after 2 weeks post-infection. Additional 
studies using fibroblasts derived from wild-type and STAT1-
knockout mice revealed the significance of STAT1 
signalling in transcriptional silencing of the amplicon-
encoded transgene in cultured cells, indicating that type I 
IFN induced by systemic delivery of amplicons may initiate 
a cascade of immune responses eventually able to suppress 
transgene expression at the transcriptional level. In a further 
study by the same group, antiviral responses were 
investigated following stereotactic HF-amplicon 
administration into the mouse striatum [39]. In this area of 
the brain, induction of type I IFN was rather modest and 
luciferase expression lasted over a year, despite dose-
dependent inflammation and infiltration of immune cells 
around the injection sites. These findings indicate that the 
spectrum of host responses can differ significantly 
depending on target organs and administration routes. 
  More recently, it was shown that GFP-expressing 
amplicon infection of cultured human foetal foreskin 
fibroblasts (HFFF-2) resulted in the induction of an 
interferon regulatory factor 3 (IRF3)-dependent antiviral 
response [34]. This innate response is characterized by the 
up-regulation of IRF7 and Toll-like receptors 3 and 4 
(TLR3/TLR4), the up-regulation of some interferon 
stimulated genes (ISG), such as ISG54 and ISG56, and the 
secretion of low levels of -IFN. These responses led to the 
establishment of an antiviral state in the amplicon-infected 
cells, which become refractory to subsequent infection with 
vesicular stomatitis virus (VSV). Furthermore, amplicon 
infection induced the nuclear translocation and subsequent 
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protein was not observed. Knockdown of IRF3 and IRF7 
using specific siRNA severely inhibited ISG and -IFN 
expression, clearly demonstrating the involvement of these 
transcription factors in the triggering of the antiviral 
response. However, further examination of the pattern 
recognition receptors (PRR) potentially involved in the 
induction of this response demonstrated that neither 
inhibition of endosome-resident TLR signalling by blocking 
lysosome maturation with ammonium chloride nor down-
regulation of TLR3 and TLR4 using specific siRNA, were 
able to abolish the cellular response to amplicons. This 
indicates that none of the TLR that are generally associated 
with IFN responses actually participates to the induction of 
this cellular response. Moreover, preliminary results from 
the same laboratory suggest that the induction of the innate 
response in HFFF-2 cells is also independent of some of the 
cytosolic recognition receptors, such as RIG-I or DAI, which 
have been described as sensors of cytosolic RNA and DNA. 
Other cytosolic receptors of nucleic acids have however 
being recently identified, but they have not yet been tested 
for amplicon recognition. These findings raise the pertinent 
question of how these cells recognize that they have been 
infected by amplicons. Most interestingly, although 
amplicon-mediated transgene expression is extremely weak 
in HFFF-2 cells, down-regulation of the induced innate 
response with IRF3 and IRF7 specific siRNA did not 
enhance transgene expression, suggesting that the low-level 
expression observed cannot be solely explained by the 
induction of the cellular innate response [40]. 
  Taken together, the above-described investigations 
clearly demonstrate that HF-amplicon infection can elicit 
innate immune and inflammatory responses, mediated by 
IRFs (IFN) and by NF-B (inflammatory cytokines), both in 
cultured cells and in vivo. While these molecules certainly 
play a major role in the induction of adaptive immune 
responses in the inoculated organisms, its role in the 
silencing of transgene expression at the cellular level is not 
clearly established, suggesting that other cellular silencing 
forces could be at work. It is important to stress that the 
IRF3/7- and NF-B-mediated responses are transient and 
that cells will rapidly resume their normal activities and gene 
expression patterns. On the other hand, although it has been 
shown that HSV-1 could induce (and inhibit) apoptotic 
responses in the infected cells [1, 10, 11], induction of 
apoptosis requires expression of virus genes that are 
normally absent from HF-amplicons. These vectors therefore 
do not induce apoptosis and are absolutely non-toxic for the 
transduced cells. 
CONSTITUTIVE ANTIVIRAL RESPONSES CAN 
INHIBIT AMPLICON-MEDIATED GENE 
EXPRESSION 
  In recent years it has became evident that a group of 
constitutively expressed proteins could also be involved in 
the negative regulation of HSV-1 gene expression [41-44]. 
These molecules, which include ND10-associated proteins, 
such as PML, sp100, ATRX or hDaxx [41-43], as well as 
ND10-independent chromatin associated proteins, such as 
the Rest-Corest-HDAC co-repressor system [44], seems to 
act mainly as transcriptional repressors. Although these 
molecules are constitutively expressed, at least some of 
them, including PML and sp100, contain interferon-
stimulated response elements (ISRE) in their regulatory 
sequences and can be further induced by -IFN, thus 
establishing a connection between these transcriptional 
silencers and the IFN-mediated system [45]. Some of these 
molecules can, however, repress expression of the incoming 
HSV-1 genome even in the absence of IFN, particularly in 
human fibroblasts, and this action can be counteracted by 
HSV-1 encoded proteins, and particularly by ICP0 [41-44]. 
  In a study conceived to investigate how amplicon vectors 
function in vivo to generate an immune response, amplicon 
vectors expressing either GFP or luciferase reporter proteins 
were used to examine the duration of expression after 
administration to mice [46]. Injection with amplicons 
expressing luciferase revealed that transgene expression 
peaked earlier than 24 hr after injection in mice. With 
amplicons expressing GFP, transgene expression peaked at 
24 hr following in vivo administration. Thus, both reporter 
proteins revealed a rather rapid and robust expression pattern 
of short duration, which appears in part to be due to gene 
silencing. Examination of cells displaying transgene 
expression suggested that amplicons could transduce a 
variety of cells, including professional antigen-presenting 
cells. Then, a very interesting study, looking at potential 
reasons underlying the observed transgene repression, 
indicated that bacterial sequences present in the amplicon 
genome could cause rapid transgene transcriptional silencing 
by forming inactive chromatin [47]. Indeed, each amplicon 
vector genome contains several copies of the original 
plasmid sequence, depending on the size of the amplicon 
plasmid [20]. Infection with amplicons devoid of bacterial 
sequences (minicircle amplicons) induced approximately 20-
fold higher transgene expression than conventional 
amplicons, and quantitative analysis of levels of transgenic 
mRNA revealed that the increase in transgene expression 
was at the transcriptional level. In addition, nude mice 
injected with minicircle amplicons exhibited 10-fold higher 
luciferase expression than mice injected with conventional 
amplicons. Furthermore, luciferase expression from 
conventional amplicons was undetectable 21 days after 
injection, whereas with the minicircle amplicons expression 
was detectable up to at least 28 days post-infection.
 These 
observations suggest that inherently expressed cellular 
proteins, perhaps recognizing naked foreign DNA entering 
the nucleus, are probably implicated in the silencing of the 
amplicon genome [47]. 
  Other studies aimed at investigating a possible role for 
the viral protein ICP0 in the inhibition of cellular silencing. 
ICP0 is an HSV-1 immediate early regulatory protein that 
plays a major role in virus infection by activating all classes 
of virus gene expression [48]. Everett and co-workers, and 
other groups, have shown that ICP0-null HSV-1 mutants can 
infect human fibroblasts and deliver the virus genome to the 
cell nucleus, but expression from the virus genome is 
immediately silenced when the cells are infected at low 
multiplicity, at least in part due to the silencing action of 
PML and other ND10-related proteins [41-43]. The 
immediate-early ICP0 protein, which contains an E3-
ubiquitin ligase activity, allows overcoming this repression 
by inducing the proteasome-dependent proteolytic 
degradation of several ND10-related proteins [48]. Since 
amplicons express neither ICP0 nor any other viral genes, it 
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observed in human fibroblasts and other cell types could be 
caused by the action of these inherent cellular silencing 
responses. In support of such hypothesis, it was observed 
that amplicons simultaneously expressing GFP under the 
control of the IE4/5 HSV-1 promoter, and wild-type ICP0 
driven by the HCMV promoter, expressed higher levels of 
GFP in human primary fibroblasts, cultured rat 
cardiomyocytes and rat neonatal cultured brain cells, than 
amplicons expressing no ICP0 or a mutated inactive form of 
ICP0 (FXE), suggesting that ICP0 played a significant role 
in suppressing a silencer activity in the amplicon-infected 
cells [21]. Since, as already quoted, one important role of 
ICP0 is to induce degradation of several ND10 constitutive 
proteins, these results lend further support to the hypothesis 
that an inherent antiviral mechanism mediated by these 
proteins is partially responsible for the silencing of 
amplicon-mediated transgene expression in human 
fibroblasts. Furthermore, preliminary results from our 
laboratory indicate that siRNA down-regulation of Sp100 
and Daxx, two regulatory proteins that localize to ND10 
bodies, resulted in at least 5-fold enhancement in the number 
of GFP-expressing normal human fibroblasts infected with 
standard amplicons [40]. 
  A very recent study, also intended to test the hypothesis 
that expression of ICP0 could overcome silencing of 
encoded transgenes, used amplicons expressing ICP0 under 
the control of its native promoter [49]. Expression of ICP0 
from these amplicons was transient and did not significantly 
alter IFN-based responses against the vector or cell 
kinetics/apoptosis of infected cells. Chromatin 
immunoprecipitation (ChIP)/PCR analysis revealed that 
conventional amplicon DNA became associated with 
HDAC1, a protein associated with transcriptional repression, 
immediately after infection. In contrast, with ICP0-
expressing amplicons the vector DNA remained relatively 
unbound by HDAC1 for at least 72 hr post-infection. In 
addition, mice systemically inoculated with amplicons 
expressing ICP0 exhibited significantly greater and more 
sustained transgene expression in their livers than did those 
receiving conventional amplicons. Thus, these results add 
further support to the notion that amplicon expression is 
submitted to silencing and that ICP0 could restore normal 
expression or at least decrease transgene silencing. 
  Lastly, the observation that the reduction of particle-
associated ICP0 levels, which results from packaging the 
amplicon genome in the presence of the transcriptional 
regulator hexamethylene bisacetylamide (HMBA),  also 
results in reduced transgene expression, provides further 
additional evidence for a role of tegumentary ICP0 in 
suppressing the silencing mechanisms that repress amplicon-
mediated transgene expression [50]. 
  Taken together, the above-described results clearly 
indicate that cellular silencing forces can act on the amplicon 
genome to block transgene expression and that these forces 
could be disabled by ICP0 or by external intervention aimed 
at suppressing them, such as RNAi procedures. 
CONCLUDING REMARKS: TOWARDS STABLE 
AMPLICON-MEDIATED TRANSGENE EXPRESSION 
  Results and observations described in this short review 
indicate that at least two types of cellular protective 
mechanisms are acting in cells infected with HF-amplicon 
vectors. A first one is mediated by constitutively expressed 
proteins that can target the incoming vector genome as soon 
as it enters the nucleus of the infected cells. The 
experimental evidence seems to support the hypothesis that 
at least two different silencing mechanisms mediated either 
by ND10-associated proteins or by HDAC1-associated 
proteins, both of which are targeted to degradation by ICP0, 
could play a major role in silencing the vector genome. In 
addition, a large set of observations sustain the notion that 
HF-amplicons could induce type I IFN-mediated and NF-
B-mediated innate immune responses, at least in some 
experimental settings. It is clear that the induction of this 
innate responses will play a role in activating the adaptive 
branch of immunity. However, the evidence favouring a role 
of these responses in the control of transgene expression at 
the cellular level is not yet conclusive. While activation of 
STAT1 in mice resulted in decreased vector expression, 
therefore suggesting that antiviral mechanisms elicited by 
type I IFN can control amplicon expression, in cultured 
human fibroblasts, down-regulation of IRF3 and 7 did not 
enhanced transgene expression. Although apparently 
contradictory, these experiments actually address different 
moments of the innate response and could be reconciled by 
the fact that, in cultured fibroblasts, the level of induced and 
secreted type I IFN was quite low, perhaps not high enough 
as to elicit the full set of antiviral proteins. More work is 
therefore required to evaluate the part played by type I IFN 
responses in the inhibition of amplicon-mediated transgene 
expression. 
  For gene therapy purposes, the critical point is if it would 
be possible to generate rationally designed amplicon vectors 
able to avoid gene silencing, therefore leading to stable 
transgene expression. A possible approach to this end is 
based on the demonstration that bacterial DNA-free 
amplicons are better armed to escape silencing due to histone 
deposition than conventional amplicons [47]. It is possible 
that other not yet identified sequences in the vector genome 
could also be involved in silencing. Identification and 
deletion of these sequences, if any, would also have a 
positive impact in expression. Alternatively, or in addition, it 
would be certainly possible to engineer the amplicon genome 
in order to express functions potentially able to inhibit 
cellular-induced gene silencing without toxicity for the 
transduced cells, or to include tissue-specific regulatory 
DNA elements, thereby forcing the amplicon genome to 
generate a transcriptionally active chromatin configuration, 
thus allowing stable expression. Previous observations using 
tissue-specific promoters or enhancers actually support the 
great interest of this approach [27-30]. 
  A different strategy would consist in the engineering the 
helper system used to generate the vectors, aiming at 
modifying the protein content of the amplicon particles. 
Using such approach, it is possible to speculate on the 
possibility of modifying the tegument or the envelope of the 
amplicon particle, in order to introduce proteins that could 
act on- and block- constitutive or inducible silencing 
systems. These approaches seems today far from reality, but 
they are not. The possibility of using helper virus genomes 
carried by bacterial artificial chromosomes, together with the 
improvement in our ability to engineer this molecule through 
homologous or site-specific recombination in bacteria, has Innate Responses in Cells Infected by HSV-1-Derived Amplicon Vectors  The Open Virology Journal, 2010, Volume 4    101 
already proven useful to modify recombinant HSV-1 vectors 
[51] and will certainly help to efficiently screen, identify, 
and modify, the virus genes that should be engineered in 
order to reach these ends. 
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